【SUNZEN 0148 交流专区】宏诚生科

哭哭鸟

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2016

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2016	30 Sep 2015	30 Sep 2016	30 Sep 2015
		$$'000	$$'000	$$'000	$$'000

1	Revenue	7,903	6,192	25,970	23,299
2	Profit/(loss) before tax	-727	-410	-2,242	208
3	Profit/(loss) for the period	-731	-468	-2,254	103
4	Profit/(loss) attributable to ordinary equity holders of the parent	-744	-467	-2,332	104
5	Basic earnings/(loss) per share (Subunit)	-0.18	-0.17	-0.58	0.04
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2000		0.1800

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2016

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2016	31 Dec 2015	31 Dec 2016	31 Dec 2015
		$$'000	$$'000	$$'000	$$'000

1	Revenue	14,043	8,922	40,013	32,222
2	Profit/(loss) before tax	1,788	-467	-454	-287
3	Profit/(loss) for the period	2,194	-450	-60	-373
4	Profit/(loss) attributable to ordinary equity holders of the parent	2,203	-452	-129	-374
5	Basic earnings/(loss) per share (Subunit)	0.49	-0.16	-0.03	-0.13
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2000		0.1800

Tony-Pua

谁对这股有研究。。。请分享。。。

Tony-Pua

SUNZEN BIOTECH BERHAD (0148)      

---

                    

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2017

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2017	31 Mar 2016	31 Mar 2017	31 Mar 2016
		$$'000	$$'000	$$'000	$$'000

1	Revenue	45,745	8,059	45,745	8,059
2	Profit/(loss) before tax	1,058	-1,210	1,058	-1,210
3	Profit/(loss) for the period	1,051	-1,214	1,051	-1,214
4	Profit/(loss) attributable to ordinary equity holders of the parent	1,019	-1,227	1,019	-1,227
5	Basic earnings/(loss) per share (Subunit)	0.21	-0.40	0.21	-0.40
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2100		0.2000

Tony-Pua

4天跌了14仙（rm0.26)！！！30%

icy97

宏诚生科拟多元化至传统中药和保健食品与饮料业务
Ahmad Naqib Idris/theedgemarkets.com
July 07, 2017 21:12 pm MYT

（吉隆坡7日讯）动物保健专家宏诚生物科技（Sunzen Biotech Bhd）拟通过收购健康保健公司益康生科制造私人有限公司（Ecolite Biotech Manufacturing）的70%股权，将业务多元化至中药，以及草药保健食品与饮料制造和贸易。

蒙亏的宏诚生科今日向大马交易所报备，已与Chum Mun Cuan和Lim Poh Chuw签署一项售股协议，以1205万令吉，收购益康525万股，相等于70%股权。

该公司将通过发行3766万新股，每股32仙来支付收购金额。

发行股份占集团扩大后股本的约7%。宏诚生科将在股东特别大会上，寻求股东批准收购和多元化计划。

“拟议收购是集团进军传统草药和保健食品与饮料制造与贸易的机会，以及多元化盈利来源并降低对现有核心业务的依赖。”

该集团补充，收购和多元化计划可为净利贡献25%或以上。

宏诚生科表示，这也将令公司在出口燕窝至中国获得立足之地。

截至2016年，益康集团通过持股70%的子公司Yanming，是获中国当局批准供应净燕的19家公司之一。

截至2016年9月30日止财政年，益康的净利为172万令吉，相比上财年净亏22万4188万令吉；营业额由1799万令吉，扬44%至3194万令吉。

宏诚生科总执行长冯俊豪表示：“这是我们转亏为盈的第一步。我们相信这个计划将为未来表现作出贡献。”

截至2016年12月31日止财政年，该集团净亏6万令吉，主要因为递延所得税的减值拨备；全年营业额从3222万令吉，增24.18%至4001万令吉。

（编译：陈慧珊）

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	SUNZEN BIOTECH BERHAD ("SUNZEN" OR THE "COMPANY")(I)        PROPOSED ACQUISITION OF 5,250,000 ORDINARY SHARES IN ECOLITE BIOTECH MANUFACTURING SDN BHD ("ECOLITE"), REPRESENTING 70% EQUITY INTEREST IN ECOLITE ; AND(II)        PROPOSED DIVERSIFICATION INTO THE MANUFACTURING AND TRADING OF TRADITIONAL CHINESE MEDICINES AND HERBAL HEALTH FOODS AND BEVERAGES
On behalf of the board of directors of SUNZEN, M&A Securities Sdn Bhd wishes to announce that on 7 July 2017, SUNZEN has entered into a share sale agreement with Chum Mun Cuan and Lim Poh Chuw (collectively, the “Vendors”) for the acquisition of 5,250,000 ordinary shares in the share capital of Ecolite, representing 70% of the total number of issued shares in Ecolite, for a purchase consideration of RM12,050,360 (“Proposed Acquisition”) to be wholly satisfied by the allotment and issuance of 37,657,375 SUNZEN Shares at an issue price of RM0.32 per SUNZEN Share. In conjunction with the Proposed Acquisition, the Company intends to undertake the proposed diversification of the business activities of SUNZEN and its subsidiaries to include the manufacturing and trading of traditional Chinese medicines and herbal health foods and beverages (“Proposed Diversification”). (The Proposed Acquisition and Proposed Diversification are collectively referred to as the “Proposals”). Kindly refer to the attachment on further details of the Proposals. This announcement is dated 7 July 2017.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5480937

Attachments 070717 - Annct.pdf

icy97

Type	Announcement
Subject	OTHERS
Description	SUNZEN BIOTECH BERHAD (the Company or Sunzen)- Subscription of Shares in Sunzen Agritechnology (Northern) Sdn. Bhd. by Sunzen Feedtech Sdn. Bhd., a wholly-owned subsidiary of the Company.
The Board of Directors of Sunzen wishes to announce that Sunzen Feedtech Sdn. Bhd. (“SFSB”), a wholly-owned subsidiary of the Company, had on 14 July 2017 subscribed 51 ordinary shares at an issue price of RM1.00 each, representing 51% equity interest in Sunzen Agritechnology (Northern) Sdn. Bhd. (Company No.: 1238788-V)(“SASB”) for a total cash consideration of RM51.00 (“Subscription”). In consequence thereof, SASB shall become a 51%-owned subsidiary of SFSB. The total number of issued share capital of SASB is 100 ordinary shares. The business activity of SASB is manufacturing and trading of biomass material and fertilizers focusing on oil palm EFB fibre, coconut fibre, palm oil mill waste and farm animal waste, and also manufacturing and distribution of house brands products such as fibre and palm based fertilizers. The Board of Directors and Shareholders and their respective shareholdings in SASB are as follows:- (I) Directors Hong Choon Hau; Lim Eng Chai; and Beh Hang Tong. (II) Shareholders and their shareholdings SFSB – 51 ordinary shares (51%); and Arah Kawasan Sdn. Bhd. - 49 ordinary shares (49%). None of the directors and/or major shareholders of the Company and/or persons connected with them have any interest, whether direct or indirect, in the Subscription. The Subscription would not have material effect on the Group’s earnings per share, net assets per share, gearing, share capital and substantial shareholders’ shareholding for the financial year ending 31 December 2017. This announcement is dated 17 July 2017.

icy97

Date of change	18 Aug 2017
Name	MADAM OOI BEE HOON
Age	51
Gender	Female
Nationality	Malaysia
Designation	Independent Director
Directorate	Independent and Non Executive
Type of change	Appointment
Qualifications	Higher School Certificate
Working experience and occupation	She has more than 16 years working experience in Telecommunication industry, which involves in the business of whosale of mobile devices and tablets. She is currently a Director of Daily Gain Teleshop Sdn. Bhd. and Best Dg Distributors Sdn. Bhd.
Directorships in public companies and listed issuers (if any)	Nil
Family relationship with any director and/or major shareholder of the listed issuer	Nil
Any conflict of interests that he/she has with the listed issuer	Nil
Details of any interest in the securities of the listed issuer or its subsidiaries	Direct - 10,400,000 ordinary shares in the Company                                                                             Indirect - 6,280,000 ordinary shares in the Company held through by her spouse and children pursuant to Section 59(11)(c) of Companies Act 2016.

icy97

宏誠生科 次季營業額翻7倍

2017年8月27日
（吉隆坡27日訊）原棕油、棕仁、棕仁殼貿易貢獻大，宏誠生科（SUNZEN，0148，創業板消費股）截至6月底次季，營業額翻漲6.6倍至7588萬令吉，且轉虧為盈，錄得147萬令吉淨利。

文告指出，公司財務表現顯著改善，可歸因于2017年首季展開的原棕油、棕仁、棕仁殼貿易業務。此外，因營運效益更高，推低了當季營運費用。

宏誠生科稱，作為全套動物保健品解決方案供應商，公司將通過行銷、開發和製造動物保健品，持續加強核心業務，該業務一直都在貢獻貿易和製造部門盈利。

該公司上半年營業額翻5.7倍至1億2162萬令吉，從淨虧159萬令吉，轉為淨賺249萬令吉。【中国报财经】

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2017

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2017	30 Jun 2016	30 Jun 2017	30 Jun 2016
		$$'000	$$'000	$$'000	$$'000

1	Revenue	75,876	10,008	121,621	18,067
2	Profit/(loss) before tax	1,426	-305	2,484	-1,515
3	Profit/(loss) for the period	1,527	-309	2,578	-1,523
4	Profit/(loss) attributable to ordinary equity holders of the parent	1,472	-361	2,491	-1,588
5	Basic earnings/(loss) per share (Subunit)	0.31	-0.10	0.52	-0.45
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2100		0.2000

icy97

icy97 发表于 8-7-2017 04:31 AM
宏诚生科拟多元化至传统中药和保健食品与饮料业务
Ahmad Naqib Idris/theedgemarkets.com
July 07, 2017 21:12 pm MYT

（吉隆坡7日讯）动物保健专家宏诚生物科技（Sunzen Biotech Bhd）拟通过收购健康保健公司 ...

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	SUNZEN BIOTECH BERHAD ("SUNZEN" OR THE "COMPANY")(I)        PROPOSED ACQUISITION OF 5,250,000 ORDINARY SHARES IN ECOLITE BIOTECH MANUFACTURING SDN BHD ("ECOLITE"), REPRESENTING 70% EQUITY INTEREST IN ECOLITE ; AND(II)        PROPOSED DIVERSIFICATION INTO THE MANUFACTURING AND TRADING OF TRADITIONAL CHINESE MEDICINES AND HERBAL HEALTH FOODS AND BEVERAGES(COLLECTIVELY, THE "PROPOSALS")
(Unless otherwise stated, the definitions used herein shall have the same meaning as defined in the announcement dated 7 July 2017) Reference is made to the announcement dated 12 September 2017 in relation to the Proposals. On behalf of the Board, M&A Securities wishes to announce that the Company does not intend to proceed with the Proposals at this juncture. This announcement is dated 7 November 2017.

icy97

宏诚取消入股益康．进军传统中草药胎死腹中

（吉隆坡10日讯）宏诚生物科技（SUNZEN,0148,创业板消费品组）展开精密审查后，决定取消入股益康生物科技制造公司（Ecolite）计划，进军传统中草药大计也宣告胎死腹中。

精密审查后发现问题

该公司7月建议，透过发行新股，以1205万360令吉总代价收购益康的70%股权。

宏诚今日在文告中说，在精密审查后发现益康和属下公司的一些问题，决定终止收购活动，该公司与卖方皆同意取消股权买卖协议。

不过，该公司强调，若卖方最终圆满解决问题，不排除考虑再次提出收购建议。

文章来源：
星洲日报·财经·2017.11.10

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	SUNZEN BIOTECH BERHAD ("SUNZEN" OR THE "COMPANY")(I)        PROPOSED ACQUISITION OF 5,250,000 ORDINARY SHARES IN ECOLITE BIOTECH MANUFACTURING SDN BHD ("ECOLITE"), REPRESENTING 70% EQUITY INTEREST IN ECOLITE FROM CHUM MUN CUAN AND LIM POH CHUW, FOR A TOTAL PURCHASE CONSIDERATION OF RM12,050,360; AND(II)        PROPOSED DIVERSIFICATION INTO THE MANUFACTURING AND TRADING OF TRADITIONAL CHINESE MEDICINES AND HERBAL HEALTH FOODS AND BEVERAGESCOLLECTIVELY, THE "PROPOSALS"
(Unless otherwise stated, the definitions used herein shall have the same meaning as defined in the announcement dated 7 July 2017) Reference is made to the announcement made on 7 November 2017 in relation to the Proposals. On behalf of the Board, M&A Securities wishes to clarify that due to some issues arising from due diligence conducted on Ecolite and its subsidiaries (“Due Diligence Issues”), the Company does not intend to proceed with the Proposals at this juncture.  As a result thereof, the Vendors and the Company have mutually agreed to terminate the SSA. If the Due Diligence Issues are subsequently resolved to the satisfaction of the Company, in future, the Company may reconsider the Proposals again or a similar corporate exercise to which the relevant announcements will be made after due and careful deliberation by the Board.   This announcement is dated 9 November 2017.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2017

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2017	30 Sep 2016	30 Sep 2017	30 Sep 2016
		$$'000	$$'000	$$'000	$$'000

1	Revenue	78,739	7,903	200,360	25,970
2	Profit/(loss) before tax	1,403	-727	3,887	-2,242
3	Profit/(loss) for the period	953	-731	3,531	-2,254
4	Profit/(loss) attributable to ordinary equity holders of the parent	874	-744	3,365	-2,332
5	Basic earnings/(loss) per share (Subunit)	0.18	-0.18	0.70	-0.58
6	Proposed/Declared dividend per share (Subunit)	0.30	0.00	0.30	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2100		0.2000

icy97

EX-date	08 Dec 2017
Entitlement date	12 Dec 2017
Entitlement time	05:00 PM
Entitlement subject	Interim Dividend
Entitlement description	A single - tier interim dividend of RM0.003 per ordinary share in respect of the financial year ending 31 December 2017
Period of interest payment	to
Financial Year End	31 Dec 2017
Share transfer book & register of members will be	to   closed from (both dates inclusive) for the purpose of determining the entitlement
Registrar or Service Provider name, address, telephone no	SYMPHONY SHARE REGISTRARS SDN BHDLevel 6, Symphony HouseBlock D13, Pusat Dagangan Dana 1Jalan PJU 1A/4647301 Petaling JayaTel:03-78418000
Payment date	27 Dec 2017
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers	12 Dec 2017
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	0.003

icy97

icy97 发表于 10-11-2017 03:40 AM
宏诚取消入股益康．进军传统中草药胎死腹中

（吉隆坡10日讯）宏诚生物科技（SUNZEN,0148,创业板消费品组）展开精密审查后，决定取消入股益康生物科技制造公司（Ecolite）计划，进军传统中草药大计也宣告胎死腹中 ...

宏诚生物科技拟1200万收购Ecolite股权
Ahmad Naqib Idris/theedgemarkets.com
January 26, 2018 20:06 pm +08

（吉隆坡26日讯）宏诚生物科技（Sunzen Biotech Bhd）与Ecolite Biotech Manufacturing私人有限公司的卖家再次签署卖股协议，以1205万令吉收购后者的70%股权。

根据文告，宏诚生物科技将通过发行4085万股新股，每股发售价为29.5仙，解决上述交易。

宏诚生物科技曾在去年7月建议上述收购计划，以让业务转亏为盈。可是，Ecolite与子公司的精密审核出现问题，导致收购计划告吹，相关单位也同意终止卖股协议。

宏诚生物科技总执行长冯俊豪说：“由于精密审核问题已经迎刃而解，因此集团重新考虑这个建议书。同时，我们相信这个收购计划将可为股东制造更多价值。”

集团计划利用其生物科技专长来发展Ecolite的业务，并表示将在中国的燕窝出口市场站稳脚跟。

宏诚生物科技强调，Ecolite通过持有70%股权的子公司Yanming将生的、清洁的和可食用的燕窝出口到中国。

我国有19家公司获得中国当局的批准，出口上述燕窝产品至中国，其中一家就是Yanming。

冯俊豪说：“展望未来，我们对这个商业创投非常乐观，因为它将打开新市场，并通过新产品线增强我们的全球分销网络。”

（编译：魏素雯）

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	SUNZEN BIOTECH BERHAD ("SUNZEN" OR THE "COMPANY")(I)        PROPOSED ACQUISITION OF 5,250,000 ORDINARY SHARES IN ECOLITE BIOTECH MANUFACTURING SDN BHD (ECOLITE), REPRESENTING 70% EQUITY INTEREST IN ECOLITE FROM CHUM MUN CUAN AND LIM POH CHUW, FOR A TOTAL PURCHASE CONSIDERATION OF RM12,050,360; AND(II)        PROPOSED DIVERSIFICATION INTO THE MANUFACTURING AND TRADING OF TRADITIONAL CHINESE MEDICINES AND HERBAL HEALTH FOODS AND BEVERAGES COLLECTIVELY, THE "PROPOSALS"
Reference is made to the announcements dated 7 July 2017, 7 November 2017 and 9 November 2017. Further to the announcements, on behalf of the Board of Directors of SUNZEN, M&A Securities Sdn Bhd wishes to inform that the issue which resulted in the previous share sale agreement between Chum Mun Cuan and Lim Poh Chuw, representing the Vendors, and Sunzen being terminated, has subsequently been resolved to the satisfaction of the Company; and the Company has reconsidered the Proposals. As such, on 26 January 2018, SUNZEN has re-entered into a new share sale agreement with the Vendors for the acquisition of 5,250,000 ordinary shares in the share capital of Ecolite, representing 70% of the total number of issued shares in Ecolite, for the same purchase consideration of RM12,050,360 as announced on 7 July 2017 to be wholly satisfied by the allotment and issuance of 40,848,678 new ordinary shares in SUNZEN at an issue price of RM0.295 per SUNZEN Share. In conjunction with the Proposed Acquisition, the Company is also undertaking the proposed diversification of the business activities of the SUNZEN group to include the manufacturing and trading of traditional Chinese medicines and herbal health foods and beverages. Kindly refer to the attachment for further details on the Proposals. This announcement is dated 26 January 2018.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5677369

Attachments 260118 - Annct.pdf

icy97

宏诚生科拟多元至衍生品买卖

2018年2月10日
（吉隆坡9日讯）宏诚生科（SUNZEN，0148，创业板）建议，多元化业务至原棕油和衍生产品买卖。

宏诚生科向马交所报备，将就上述事项召开特大寻求批准。

宏诚生科形容这是一个机缘巧合的商业策略。2016年杪时，该公司为生产名为powder fat的饲料，寻求精制硬棕（RBD palm stearin）的稳定供应，但当时市场却供应短缺。

因此，宏诚生科开始向厂家购买原棕油，再交给精炼商转成精制硬棕。

然而在分裂过程中亦会生产精制软棕，而公司又没法出售精制软棕，因此宏诚生科向精炼商购买精制硬棕，然后再售原棕油予对方来从中获利。

自此之后，宏诚生科开始收到来自精炼商的订单，而通过交易原棕油和衍生产品公司收获了可观的净利。

2业务贡献净利98%

截至去年9月杪，原棕油和衍生产品交易业务分别贡献公司营收和净利83.24%和97.51%。

总执行长冯俊豪在文告中指出，为确保新业务成功发展，公司已为人在行内有丰富经验的卢利达（译音）来掌舵相关业务。

“我们有信心，原棕油和衍生产品买卖在未来将为公司带来亮眼业绩。”【e南洋】

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	SUNZEN BIOTECH BERHAD ("SUNZEN" OR THE "COMPANY") PROPOSED RATIFICATION OF THE DIVERSIFICATION OF THE BUSINESS OF SUNZEN AND ITS SUBSIDIARIES INTO TRADING OF CRUDE PALM OIL AND DERIVATIVE PRODUCTS ("PROPOSED RATIFICATION")
M&A Securities Sdn Bhd wishes to announce that the Company proposes to ratify its diversification of its business and its subsidiaries into trading of crude palm oil and derivative products.  The Board of Directors of SUNZEN proposes to seek the approval for the Proposed Ratification from the shareholders at an extraordinary general meeting of the Company to be convened. Kindly refer to the attachment on further details of the Proposed Ratification. This announcement is dated 9 February 2018.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5688801

Attachments PP - Annct.pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2017

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2017	31 Dec 2016	31 Dec 2017	31 Dec 2016
		$$'000	$$'000	$$'000	$$'000

1	Revenue	103,091	14,043	303,451	40,013
2	Profit/(loss) before tax	125	1,788	4,012	-455
3	Profit/(loss) for the period	109	2,194	3,640	-60
4	Profit/(loss) attributable to ordinary equity holders of the parent	109	2,203	3,474	-130
5	Basic earnings/(loss) per share (Subunit)	0.02	0.49	0.72	-0.03
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.30	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.2100		0.2000

icy97

Date of change	27 Feb 2018
Name	MR LIM BOON KUAN
Age	51
Gender	Male
Nationality	Malaysia
Type of change	Appointment
Designation	Chief Financial Officer
Qualifications	He is a Member of Malaysian Institute of Accountants and fellowship of ACCA.
Working experience and occupation	He started his career as financial controller of DBX Express Services Sdn Bhd. In October 2001 he joined Metroplex Berhad as Senior Accountant. In 2003 he joined Darco Water Technologies Pte Ltd as Director of Business Development and Group Financial Controller. He joined YKGI Berhad as Chief Financial Officer in 2015 and subsequently moved on to Kumpulan Powernet Berhad  in April 2016 prior joining Sunzen Biotech Berhad.

icy97

Date of change	18 Aug 2017
Name	MADAM OOI BEE HOON
Age	51
Gender	Female
Nationality	Malaysia
Designation	Independent Director
Directorate	Independent and Non Executive
Type of change	Appointment
Qualifications	Higher School Certificate
Working experience and occupation	She has more than 16 years working experience in Telecommunication industry, which involves in the business of whosale of mobile devices and tablets. She is currently a Director of Daily Gain Teleshop Sdn. Bhd. and Best Dg Distributors Sdn. Bhd.
Directorships in public companies and listed issuers (if any)	Nil
Family relationship with any director and/or major shareholder of the listed issuer	Nil
Any conflict of interests that he/she has with the listed issuer	Nil
Details of any interest in the securities of the listed issuer or its subsidiaries	Direct - 10,400,000 ordinary shares in the Company.Indirect - 6,280,000 ordinary shares in the Company held through by her spouse and children pursuant to Section 59(11)(c) of Companies Act 2016.Direct - 2,000,000 Warrants 2016/2021 in the Company.Indirect - 2,106,000 Warrants 2016/2021 in the Company held through by her spouse pursuant to Section 59(11)(c) of Companies Act 2016.

icy97

Type	Announcement
Subject	OTHERS
Description	SUNZEN BIOTECH BERHAD ("SUNZEN" OR "THE COMPANY")- PROPOSED ACQUISITION OF SHARES IN AMPLIO INGREDIENTS SDN. BHD. BY THE COMPANY
The Board of Directors of Sunzen is pleased to announce that on 8 May 2018 the Company entered into a Sales of Shares Agreement ("SSA") and Shareholders' Agreement ("SA") with Cheong Wai Loon (NRIC No. 801201-14-5741) and Low Yuan Heng (NRIC No. 781205-01-6183) ["Collectively known as "Vendors"] for the acquisition of 700,000 ordinary shares, representing 70% of the total issued share capital of Amplio Ingredients Sdn. Bhd. (Company No. 1045181-W) ("Amplio") for a total Purchase Price of RM2,800,000.00 (Ringgit Malaysia Two Million Eight Hundred Thousand only) ("Purchase Price") ["Proposed Acquisition"]. Upon completion of the Proposed Acquisition, the Company shall own 70% of the shares in Amplio, which shall be a subsidiary of the Company. The full texts of the announcement is attached.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5786961

Attachments Announcement-Acquisition of Shares in Amplio.pdf